Zoetis Inc. (ZTS) — Fair Value Analysis

Base-case fair value (P50): $88.79 · Current price: $74.80 · Verdict: Undervalued

The Verdict on ZTS

Based on comprehensive Monte Carlo simulations, Zoetis (ZTS) is currently assessed as Deeply Undervalued. Our median fair value (P50) for ZTS stands at $88.79, significantly above its current trading price of $74.80. This indicates a substantial +18.7% potential for investors from current levels, challenging any notion of ZTS being overvalued. The simulation results consistently point to a strong disconnect between the market's current valuation and ZTS's intrinsic value, suggesting a compelling entry point.

How ZTS stacks up against Healthcare

Within the Healthcare sector, Zoetis maintains an "average" quality tier, reflecting its operational and financial health relative to peers. Despite this average standing, the Monte Carlo analysis underscores the deep undervaluation of ZTS at $74.80, with a P50 target of $88.79. This isn't a reflection of exceptional operational outperformance relative to its quality tier, but rather a robust indication that the market is not fully pricing in the company's future cash flows as modeled across thousands of forward scenarios. The +18.7% gap is substantial, even for a company positioned as "average" in its sector quality.

What this means for investors

For investors considering Zoetis, the current valuation presents a significant opportunity. The Monte Carlo simulations project a median fair value of $88.79, implying a +18.7% potential from the current $74.80. While ZTS's quality tier is average, this undervaluation is driven by a deep discount to intrinsic value rather than extraordinary quality metrics. Our FairCurve analysis suggests the market hasn't fully appreciated ZTS's long-term prospects. To see the full bear/bull distribution and track ZTS's fair value as new fundamentals are released, sign up for FairCurve today.